Investor Relations

Corporate Profile

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).

Change

Volume

52 Week High

52 Week Low

Jun 13, 2021 7:33 AM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 10, 2021

FOSTER CITY, Calif. --(BUSINESS WIRE)--Jun. 10, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on May 10, 2021 , the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 191,400 shares of common stock to

Mirum Pharmaceuticals Appoints Veteran Biotechnology Executive Carol L. Brosgart, M.D. to Board of Directors

June 7, 2021

FOSTER CITY, Calif. --(BUSINESS WIRE)--Jun. 7, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of Carol L. Brosgart , M.D., clinical professor of medicine, biostatistics and epidemiology, University of California, San Francisco , as an independent director to its

Mirum Pharmaceuticals Showcases Maralixibat Transplant-Free Survival Data for Progressive Familial Intrahepatic Cholestasis and Long-Term Safety Analyses for Alagille Syndrome during WCPGHAN Annual Meeting

June 3, 2021

- Maralixibat-treated patients achieving serum bile acid control have improved five-year native liver survival; nominated for prestigious Alex Mowat Prize for best oral presentation in hepatology. - Safety data from more than five years of maralixibat treatment across three Phase 2 ALGS studies

Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium at the 6th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition (WCPGHAN) Annual Meeting 2021

May 26, 2021

- Integrated safety analysis on gastrointestinal tolerability of maralixibat in patients with Alagille syndrome presented in poster session. - Five-year analysis demonstrating improvements in transplant-free survival for patients with PFIC2 featured in oral presentation; abstract nominated for the

Events

WCPGHAN Annual Meeting

Jun 2 - Jun 5, 2021

Q1 2021 Financial Results Conference Call

May 6, 2021 at 4:30 PM EDT

Click here for Webcast

Oppenheimer 31st Annual Healthcare Conference

Mar 17, 2021 at 3:50 PM EDT

Investor Relations

Investor Relations

Corporate Profile

Header Menu